33 results on '"HammerstrØm, Jens"'
Search Results
2. Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism
- Author
-
Mahmoodi, Bakhtawar K, Cushman, Mary, Anne Næss, Inger, Allison, Matthew A, Bos, Willem J, Brækkan, Sigrid K, Cannegieter, Suzanne C, Gansevoort, Ron T, Gona, Philimon N, Hammerstrøm, Jens, Hansen, John-Bjarne, Heckbert, Susan, Holst, Anders G, Lakoski, Susan G, Lutsey, Pamela L, Manson, JoAnn E, Martin, Lisa W, Matsushita, Kunihiro, Meijer, Karina, Overvad, Kim, Prescott, Eva, Puurunen, Marja, Rossouw, Jacques E, Sang, Yingying, Severinsen, Marianne T, Ten Berg, Jur, Folsom, Aaron R, and Zakai, Neil A
- Subjects
Epidemiology ,Biomedical and Clinical Sciences ,Health Sciences ,Tobacco ,Hematology ,Prevention ,Cardiovascular ,Clinical Research ,Tobacco Smoke and Health ,Good Health and Well Being ,Age Factors ,Blood Pressure ,Body Mass Index ,Diabetes Complications ,Humans ,Hyperlipidemias ,Hypertension ,Lipids ,Proportional Hazards Models ,Prospective Studies ,Pulmonary Embolism ,Risk Factors ,Sex Factors ,Smoking ,Venous Thromboembolism ,Venous Thrombosis ,cardiovascular disease ,diabetes mellitus ,hyperlipidemia ,hypertension ,risk factors ,smoking ,venous thromboembolism ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences ,Sports science and exercise - Abstract
BackgroundMuch controversy surrounds the association of traditional cardiovascular disease risk factors with venous thromboembolism (VTE).MethodsWe performed an individual level random-effect meta-analysis including 9 prospective studies with measured baseline cardiovascular disease risk factors and validated VTE events. Definitions were harmonized across studies. Traditional cardiovascular disease risk factors were modeled categorically and continuously using restricted cubic splines. Estimates were obtained for overall VTE, provoked VTE (ie, VTE occurring in the presence of 1 or more established VTE risk factors), and unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.ResultsThe studies included 244 865 participants with 4910 VTE events occurring during a mean follow-up of 4.7 to 19.7 years per study. Age, sex, and body mass index-adjusted hazard ratios for overall VTE were 0.98 (95% confidence interval [CI]: 0.89-1.07) for hypertension, 0.97 (95% CI: 0.88-1.08) for hyperlipidemia, 1.01 (95% CI: 0.89-1.15) for diabetes mellitus, and 1.19 (95% CI: 1.08-1.32) for current smoking. After full adjustment, these estimates were numerically similar. When modeled continuously, an inverse association was observed for systolic blood pressure (hazard ratio=0.79 [95% CI: 0.68-0.92] at systolic blood pressure 160 vs 110 mm Hg) but not for diastolic blood pressure or lipid measures with VTE. An important finding from VTE subtype analyses was that cigarette smoking was associated with provoked but not unprovoked VTE. Fully adjusted hazard ratios for the associations of current smoking with provoked and unprovoked VTE were 1.36 (95% CI: 1.22-1.52) and 1.08 (95% CI: 0.90-1.29), respectively.ConclusionsExcept for the association between cigarette smoking and provoked VTE, which is potentially mediated through comorbid conditions such as cancer, the modifiable traditional cardiovascular disease risk factors are not associated with increased VTE risk. Higher systolic blood pressure showed an inverse association with VTE.
- Published
- 2017
3. Association of smoking and cancer with the risk of venous thromboembolism: the Scandinavian Thrombosis and Cancer cohort
- Author
-
Paulsen, Benedikte, primary, Gran, Olga V., additional, Severinsen, Marianne T., additional, Hammerstrøm, Jens, additional, Kristensen, Søren R., additional, Cannegieter, Suzanne C., additional, Skille, Hanne, additional, Tjønneland, Anne, additional, Rosendaal, Frits R., additional, Overvad, Kim, additional, Næss, Inger Anne, additional, Hansen, John-Bjarne, additional, and Brækkan, Sigrid K., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort
- Author
-
Gade, Inger Lise, additional, Brækkan, Sigrid, additional, Næss, Inger Anne, additional, Hansen, John-Bjarne, additional, Cannegieter, Suzanne, additional, Rosendaal, Frits, additional, Overvad, Kim, additional, Hindberg, Kristian, additional, Hammerstrøm, Jens, additional, Gran, Olga, additional, Tjønneland, Anne, additional, Severinsen, Marianne, additional, and Kristensen, Søren, additional
- Published
- 2018
- Full Text
- View/download PDF
5. Risk of venous thrombo-embolism in female malignancies:the Scandinavian Thrombosis and Cancer Cohort
- Author
-
Gade, Inger Lise, Brækkan, Sigrid, Næss, Inger Anne, Hansen, John-Bjarne, Rosendaal, Frits, Cannegieter, Suzanne, Overvad, Kim, Jensvoll, Hilde, Hammerstrøm, Jens, Blix, Kristine, Eriksen, Helle Højmark, Kristensen, Søren Risom, and Severinsen, Marianne Tang
- Published
- 2016
6. Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort
- Author
-
Jensvoll, Hilde, Severinsen, Marianne T., Hammerstrøm, Jens, Brækkan, Sigrid Kufaas, Kristensen, Søren R., Cannegieter, Suzanne C., Blix, Kristine, Tjønneland, Anne, Rosendaal, Frits Richard, Dziewiecka, Olga, Overvad, Kim, Næss, Inger Anne, and Hansen, John-Bjarne
- Subjects
pulmonary embolism ,VDP::Medical disciplines: 700::Clinical medical disciplines: 750 ,venous thromboembolism ,VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750 ,cancer ,Clinical Epidemiology ,incidence rates ,population-based cohort ,prospective ,person-years - Abstract
Hilde Jensvoll,1,2 Marianne T Severinsen,3,4 Jens Hammerstrøm,5 Sigrid K Brækkan,1,2 Søren R Kristensen,4,6 Suzanne C Cannegieter,7 Kristine Blix,1,2 Anne Tjønneland,8 Frits R Rosendaal,1,7,9 Olga Dziewiecka,1 Kim Overvad,10,11 Inger Anne Næss,12 John-Bjarne Hansen1,21Department of Clinical Medicine, KG Jebsen – Thrombosis Research and Expertise Center (TREC), UiT – The Arctic University of Norway, 2Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway; 3Department of Hematology, Aalborg University Hospital, 4Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 5Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; 6Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark; 7Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; 8Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark; 9Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands; 10Department of Cardiology, Aalborg University Hospital, Aalborg, 11Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark; 12Department of Hematology, Trondheim University Hospital, Trondheim, NorwayBackground: Although venous thromboembolism (VTE) is a known common complication in cancer patients, there is limited knowledge on patient-related and cancer-specific risk factors in the general population. The Scandinavian Thrombosis and Cancer (STAC) Cohort was established by merging individual data from three large Scandinavian cohorts (The Tromsø Study, the second Nord-Trøndelag Health Study, and the Danish Diet, Cancer and Health Study). Here, we present the profile of the STAC cohort and provide age-specific incidence rates of VTE and cancerMethods: The STAC cohort includes 144,952 subjects aged 19–101 years without previous VTE or cancer. Baseline information collected in 1993–1997 included physical examination, self-administered questionnaires, and blood samples. Validated VTE events and cancer diagnoses were registered up to 2007–2012.Results: There were 2,444 VTE events (1.4 per 1,000 person-years [PY]) during follow-up, and the incidence increased exponentially from 0.3 per 1,000 PY in subjects aged 20–29 years to 6.4 per 1,000 PY in subjects aged 80+. Overall, 51% of the VTE events were provoked, and cancer was the most common provoking factor (19%), followed by immobilization and surgery (both 15%). In total, 19,757 subjects developed cancer during follow-up (9.8 per 1,000 PY), and the 5-year age-specific incidence rates of cancer were coherent with corresponding rates from the Norwegian Cancer Registry.Conclusion: The STAC cohort will provide a unique opportunity to explore the epidemiology and impact of genetic and environmental patient-related and cancer-specific risk factors for VTE in the general population.Keywords: venous thromboembolism, incidence rates, person-years, pulmonary embolism, population-based cohort, prospective, cancer
- Published
- 2015
7. Risk of Venous Thromboembolism in Hematological Malignancies: The Scandinavian Thrombosis and Cancer Cohort
- Author
-
Gade, Inger Lise, primary, Brækkan, Sigrid K, additional, Næss, Inger Anne, additional, Hansen, John-Bjarne, additional, Rosendaal, Frits, additional, Cannegieter, Suzanne C, additional, Overvad, Kim, additional, Jensvoll, Hilde, additional, Hammerstrøm, Jens, additional, Blix, Kristine, additional, Tjønneland, Anne, additional, Kristensen, Søren R, additional, and Severinsen, Marianne Tang, additional
- Published
- 2015
- Full Text
- View/download PDF
8. Høydosebehandling med autolog stamcellestøtte ved lymfom i Norge 1987 – 2008
- Author
-
Smeland, Knut Bjøro, primary, Kiserud, Cecilie E., primary, Lauritzsen, Grete F., primary, Blystad, Anne Kirsti, primary, Fagerli, Unn Merete, primary, Fluge, Øystein, primary, Fosså, Alexander, primary, Hammerstrøm, Jens, primary, Kolstad, Arne, primary, Loge, Jon Håvard, primary, Maisenhølder, Martin, primary, Østenstad, Bjørn, primary, Kvaløy, Stein, primary, and Holte, Harald, primary
- Published
- 2013
- Full Text
- View/download PDF
9. Høydosebehandling med autolog stamcellestøtte ved lymfom – fra utprøvende til standard behandling
- Author
-
Smeland, Knut Bjøro, primary, Kiserud, Cecilie E., primary, Lauritzsen, Grete F., primary, Fosså, Alexander, primary, Hammerstrøm, Jens, primary, Jetne, Vidar, primary, Kolstad, Arne, primary, Kvalheim, Gunnar, primary, Loge, Jon Håvard, primary, Løkeland, Turid, primary, Tangen, Jon Magnus, primary, Holte, Harald, primary, and Kvaløy, Stein, primary
- Published
- 2013
- Full Text
- View/download PDF
10. Association of Mild to Moderate Chronic Kidney Disease With Venous Thromboembolism
- Author
-
Mahmoodi, Bakhtawar K., primary, Gansevoort, Ron T., additional, Næss, Inger Anne, additional, Lutsey, Pamela L., additional, Brækkan, Sigrid K., additional, Veeger, Nic J.G.M., additional, Brodin, Ellen E., additional, Meijer, Karina, additional, Sang, Yingying, additional, Matsushita, Kunihiro, additional, Hallan, Stein I., additional, Hammerstrøm, Jens, additional, Cannegieter, Suzanne C., additional, Astor, Brad C., additional, Coresh, Josef, additional, Folsom, Aaron R., additional, Hansen, John-Bjarne, additional, and Cushman, Mary, additional
- Published
- 2012
- Full Text
- View/download PDF
11. Abstract P255: Association of Mild Chronic Kidney Disease with Venous Thromboembolism: Pooled Analysis of Prospective General Population Cohorts
- Author
-
Mahmoodi, Bakhtawar K, primary, Gansevoort, Ron T, additional, Naess, Inger Anne, additional, Lutsey, Pamela L, additional, Braekkan, Sigrid K, additional, Veeger, Nic J, additional, Brodin, Ellen E, additional, Meijer, Karina, additional, Sang, Yingying, additional, Matsushita, Kunihiro, additional, Hallan, Stein, additional, Hammerstrøm, Jens, additional, Astor, Brad C, additional, Coresh, Josef, additional, Folsom, Aaron R, additional, Hansen, John-Bjarne, additional, and Cushman, Mary, additional
- Published
- 2012
- Full Text
- View/download PDF
12. The Risk of Venous Thrombosis Related to Increase in Body Mass Index Is Mediated by Factor VIII Induced APC-Resistance.
- Author
-
Lijfering, Willem M, primary, Christiansen, Sverre C, additional, Naess, Inger-Anne, additional, Hammerstrøm, Jens, additional, van Hylckama Vlieg, Astrid, additional, Rosendaal, Frits, additional, and Cannegieter, Suzanne C, additional
- Published
- 2009
- Full Text
- View/download PDF
13. A Replication Study of Gene Variants Associated with Venous Thrombosis. Results From a Population-Based Nested Case-Cohort Study.
- Author
-
Lijfering, Willem M, primary, Bezemer, Irene D, additional, Christiansen, Sverre C, additional, Naess, Inger-Anne, additional, Rosendaal, Frits, additional, Hammerstrøm, Jens, additional, and Cannegieter, Suzanne C, additional
- Published
- 2009
- Full Text
- View/download PDF
14. Hyperferritinemia Is Associated with Insulin Resistance and Fatty Liver in Patients without Iron Overload
- Author
-
Brudevold, Robert, primary, Hole, Torstein, additional, and Hammerstrøm, Jens, additional
- Published
- 2008
- Full Text
- View/download PDF
15. Inflammatory Cytokines as Risk Factors for a First Venous Thrombosis: A Prospective Population-Based Study
- Author
-
Christiansen, Sverre C, primary, Næss, Inger Anne, additional, Cannegieter, Suzanne C, additional, Hammerstrøm, Jens, additional, Rosendaal, Frits R, additional, and Reitsma, Pieter H, additional
- Published
- 2006
- Full Text
- View/download PDF
16. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis
- Author
-
Aasarød, Knut, primary, Bostad, Leif, additional, Hammerstrøm, Jens, additional, Jørstad, Størker, additional, and Iversen, Bjarne M., additional
- Published
- 2001
- Full Text
- View/download PDF
17. Wegener's granulomatosis: clinical course in 108 patients with renal involvement
- Author
-
Aasarød, Knut, primary, Iversen, Bjarne M., additional, Hammerstrøm, Jens, additional, Bostad, Leif, additional, Vatten, Lars, additional, and Jørstad, Størker, additional
- Published
- 2000
- Full Text
- View/download PDF
18. In Vitro Cultured Human Monocytes Release Fibroblast Proliferation Factor(s) Different From Interleukin 1
- Author
-
Austgulen, Rigmor, Hammerstrøm, Jens, and Nissen‐Meyer, Jon
- Abstract
Human monocytes cultured in vitro released factors with growth stimulatory effect upon human dermal fibroblasts. Monocytes in RPMI 1640 released a growth enhancing activity in nearly constant amounts during in vitro differentiation to macrophage‐like cells. The growth stimulatory effect mediated by supernatants was reduced when lipopolysaccha‐ride (LPS) or opsonized zymosan particles (OpZ) were added to monocytes during the first 5 days of in vitro culture, thereafter reaching similar levels. The release of interleukin 1 (IL‐1) from monocytes was restricted to the first 2 days of culture. IL‐1 production by unstimulated monocytes was negligible, while LPS induced a high release of IL‐1 from monocytes. A rabbit antibody against human IL‐1 abolished the IL‐1 activity of the monocyte supernatants as assessed in a mouse thymocyte proliferation assay, but caused only a small reduction of the fibroblast proliferation activity. Thus, the fibroblast growth stimulatory activity mediated by monocytes was caused by factor(s) in addition to IL‐1.
- Published
- 1987
- Full Text
- View/download PDF
19. High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.
- Author
-
Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, and Holte H
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy statistics & numerical data, Female, Humans, Lymphoma mortality, Male, Middle Aged, Norway epidemiology, Survival Rate, Transplantation, Autologous statistics & numerical data, Young Adult, Hematopoietic Stem Cell Transplantation statistics & numerical data, Lymphoma therapy
- Abstract
Background: High-dose therapy with autologous stem cell support (HDT) has been a treatment option for lymphomas in Norway for 25 years. The purpose of the article was to describe the use of the therapy for lymphomas for the country as a whole and by health region, and to reveal the overall survival rate., Method: All lymphoma patients ≥ 18 years who received HDT in Norway in the period 1987-2008 are included. Patients, diagnostics and treatment are identified for each hospital. Data for the population base have been retrieved from Statistics Norway., Results: Altogether 726 lymphoma patients received HDT in Norway in the period 1987-2008, with an annual average of 0.72 per 100,000 inhabitants. The annual number of treatments increased until 2004 and has since been stable. The average number of treatments per 100,000 inhabitants per year was 0.94 for Northern Norway Health Region, 0.80 for South-Eastern Norway Health Region, 0.58 for Central Norway Health Region and 0.55 for Western Norway Health Region. Early mortality (death within 100 days) was 6%. Ten-year overall survival was 55% (95% CI 51-59%), and Hodgkin's lymphoma had the best survival of the lymphoma groups (p = 0.01)., Interpretation: The annual number of HDT increased gradually until 2004. The use of the treatment varied according to the patients' place of residence at the time of diagnosis, and was most frequently used for patients belonging to Northern Norway Health Region. More than half of the lymphoma patients are alive ten years after the treatment.
- Published
- 2013
- Full Text
- View/download PDF
20. High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment.
- Author
-
Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, and Kvaløy S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy history, Critical Pathways, History, 20th Century, Humans, Lymphoma history, Norway, Practice Guidelines as Topic, Transplantation, Autologous history, Antineoplastic Combined Chemotherapy Protocols history, Hematopoietic Stem Cell Transplantation history, Lymphoma therapy
- Abstract
High-dose therapy with autologous stem cell support (HDT) has been a therapeutic option for lymphomas in Norway since as far back as 1987. By restoring bone marrow function through reinfusion of the patient's own stem cells, it is possible to administer cancer treatment in higher and otherwise lethal doses, and thereby achieve better treatment results. Originally stem cells were harvested from bone marrow and the high-dose therapy included total body irradiation, but since the mid 1990s stem cells have been harvested by apheresis and the high-dose therapy has consisted of chemotherapy alone (BEAM chemotherapy). In 1995 the treatment was regionalised and since then it has been performed in all health regions. The HDT procedure was introduced as an experimental treatment in clinical studies with international collaboration. The indications have changed over time, and this is now established treatment for a number of types of lymphoma.
- Published
- 2013
- Full Text
- View/download PDF
21. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2).
- Author
-
Quist-Paulsen P, Naess IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR, and Hammerstrøm J
- Subjects
- Aged, Aged, 80 and over, Cardiovascular Diseases etiology, Case-Control Studies, Cohort Studies, Female, Humans, Male, Middle Aged, Norway epidemiology, Prospective Studies, Risk Factors, Venous Thrombosis etiology, Cardiovascular Diseases blood, Cardiovascular Diseases epidemiology, Population Surveillance, Venous Thrombosis blood, Venous Thrombosis epidemiology
- Abstract
Background: An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking. The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis., Design and Methods: Cases who had a first venous thrombosis (n=515) and matched controls (n=1,505) were identified from a population-based, nested, case-cohort study (the HUNT 2 study) comprising 71% (n=66,140) of the adult residents of Nord-Trøndelag County in Norway., Results: The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 (95% confidence interval: 1.2-2.2) compared to subjects with C-reactive protein in the lowest quintile. This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile. Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [odds ratio 1.3 (95% confidence interval: 1.1-1.6)]. Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile. There were no associations between the risk of venous thrombosis and total cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, triglycerides, glucose or smoking. We confirmed the positive association between obesity and venous thrombosis., Conclusions: C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis. Blood pressure was inversely correlated to venous thrombosis. These findings should be confirmed by further investigations.
- Published
- 2010
- Full Text
- View/download PDF
22. [A previously healthy male with progressive high fever episodes].
- Author
-
Moser KH, Rødevand E, Hammerstrøm J, Steinum HO, and Hannula R
- Subjects
- Amphotericin B administration & dosage, Antiprotozoal Agents administration & dosage, Bone Marrow parasitology, Diagnosis, Differential, Humans, Leishmaniasis, Visceral drug therapy, Lupus Erythematosus, Systemic diagnosis, Male, Middle Aged, Recurrence, Fever of Unknown Origin diagnosis, Leishmaniasis, Visceral diagnosis
- Published
- 2008
23. [Bacteremia in hematological malignant disorders].
- Author
-
Hammerstrøm J, Røym AL, and Gran FW
- Subjects
- Aminoglycosides therapeutic use, Anti-Bacterial Agents therapeutic use, Bacteremia drug therapy, Bacterial Infections drug therapy, Drug Resistance, Bacterial, Hematologic Neoplasms drug therapy, Hematologic Neoplasms immunology, Humans, Leukemia drug therapy, Leukemia immunology, Leukemia microbiology, Lymphoma drug therapy, Lymphoma immunology, Lymphoma microbiology, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes immunology, Myelodysplastic Syndromes microbiology, Neutropenia chemically induced, Opportunistic Infections drug therapy, Penicillin G therapeutic use, Survival Analysis, Antineoplastic Agents adverse effects, Bacteremia microbiology, Bacterial Infections microbiology, Hematologic Neoplasms microbiology, Opportunistic Infections microbiology
- Abstract
Background: Bacteremia frequently complicates cytostatic treatment of hematological malignancies. Initial antibiotic treatment is chosen empirically before the results of cultures are available. Rational choices depend on updated knowledge of microbial resistance patterns. We have examined microorganisms in blood cultures over a 10-year period and compared them with the preceding 5-year period., Material and Methods: We analyzed isolates from blood cultures in patients with a hematological malignant disorder treated in the Hematology Unit, St. Olavs Hospital during the years 1995 - 2005., Results: We found 373 isolates and 322 episodes of bacteremia in 225 patients. Most patients had acute leukemia or myeloma, with neutropenia after cytostatic treatment. The dominating pathogens were Escherichia coli (20 %), coagulase-negative staphylococci (13 %) and alpha-haemolytic streptococci (10 %). Enterococcus infections seem to occur more frequently and were associated with a high mortality. Gram-negative organisms constituted 48 % and gram-positive organisms 48 % of the isolates. About 3 / 4 of the patients had infections with penicillin-resistant bacteria. There was a low prevalence of organisms resistant to aminoglycoside. Acute leukemia patients with bacteremia had a 30-days all-cause mortality of 10.3 %., Interpretation: We found small changes in the pattern of pathogens and antibiotic resistance over time. The rates of antibiotic resistance were favorable compared to other European countries. The mortality rate seems to be unchanged and acceptable. Penicillin G and aminoglycoside can still be considered as first-line treatment for suspected bacteremia in neutropenic patients in Norway.
- Published
- 2008
24. [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support].
- Author
-
Schjesvold FH, Sjo M, Tangen JM, Hammerstrøm J, and Brinch L
- Subjects
- Aged, Amyloidosis diagnosis, Amyloidosis drug therapy, Amyloidosis mortality, Antineoplastic Agents, Alkylating adverse effects, Antineoplastic Agents, Alkylating therapeutic use, Combined Modality Therapy, Humans, Melphalan adverse effects, Melphalan therapeutic use, Middle Aged, Practice Patterns, Physicians', Retrospective Studies, Surveys and Questionnaires, Survival Rate, Transplantation, Autologous, Amyloidosis therapy, Stem Cell Transplantation adverse effects
- Abstract
Background: AL-amyloidosis is a serious disease with a short median survival without treatment. Treatment with high-dose melphalan with autologous stem cell support (HMAS) has a potential to increase survival, but is associated with toxicity and mortality. In this paper we report the Norwegian results retrospectively., Material and Methods: We used questionnaires and had personal contact with a local physician from each hospital with HMAS experience. Diagnosis and treatment were evaluated according to the guidelines at the time of treatment, and the results were compared to internationally published reports., Results: Stem cell harvesting was attempted in 18 patients from 1997 to 2006. 15 of these received HMAS treatment. Treatment-related mortality was 20%, and 5 of 11 (45%) had an organ response. Median survival was not reached within the 55-month median observation time. The course of the disease was more complicated when known risk factors for HMAS treatment were present, such as reduced kidney function, advanced heart involvement, reduced performance status, and multiorgan disease. Three of 18 patients were not diagnosed according to relevant guidelines. In seven of 12 patients the response to treatment was not evaluated adequately with respect to haematology., Interpretation: AL-amyloidosis is a difficult diagnosis and the condition is probably under-diagnosed in Norway. The results of HMAS treatment in Norway are comparable with those in published reports from centres abroad. The follow-up of patients should be improved.
- Published
- 2008
25. [An unusual cause of a common condition].
- Author
-
Hammerstrøm J
- Subjects
- Anemia, Iron-Deficiency diagnosis, Humans, Iron blood, Anemia, Iron-Deficiency etiology, Iron urine
- Published
- 2006
26. Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004.
- Author
-
Lamvik J, Waage A, Wahl SG, Naess I, Paulsen PQ, and Hammerstrøm J
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Burkitt Lymphoma pathology, Burkitt Lymphoma therapy, Female, Hematopoietic Stem Cells pathology, Humans, Incidence, Male, Middle Aged, Norway epidemiology, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Burkitt Lymphoma epidemiology, Precursor Cell Lymphoblastic Leukemia-Lymphoma epidemiology
- Abstract
We report a population-based investigation on adult acute precursor B lymphoblastic leukemia, Burkitt's lymphoma and T lymphoblastic lymphoma in a defined geographic area. The age-adjusted incidence rates for the three diagnostic groups were 0.47, 0.16 and 0.2 per 100,000 per year, respectively. Clinical characteristics and outcome following treatment are reported.
- Published
- 2006
27. [High-dose treatment with autologous stem cell support in a Norwegian region].
- Author
-
Hammerstrøm J, Aasland IL, Telhaug R, Moen T, Lødemel B, Sørum Y, Brudevold R, Herlofsen O, Sørbø JH, Almvik T, and Lamvik J
- Subjects
- Adult, Aged, Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Female, Humans, Lymphoma drug therapy, Lymphoma mortality, Lymphoma therapy, Male, Middle Aged, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Multiple Myeloma therapy, Neoplasms drug therapy, Neoplasms mortality, Norway, Quality Indicators, Health Care, Retrospective Studies, Testicular Neoplasms drug therapy, Testicular Neoplasms mortality, Testicular Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Hematopoietic Stem Cell Transplantation standards, Neoplasms therapy
- Abstract
Background: The introduction of high-dose treatment with autologous stem cell support (HMAS) in Norwegian regional hospitals in the early 1990s was controversial. Concerns that low numbers of patients would lead to unacceptably low quality were expressed., Material and Methods: We present treatment results in the health region of Middle Norway, based on nearly 10 years of experience and 100 treated patients. Myeloma results are compared to the results from other Norwegian regional hospitals., Results and Interpretation: Overall survival for multiple myeloma after HMAS (median 6.8 years) was not significantly different in middle Norway compared to the rest of the country, and comparable with published results. Treatment-related mortality was low (1.2%). Results and complications in malignant lymphoma, breast cancer or germ cell tumours are described. HMAS can be satisfactorily given in a regional hospital with relatively few patients.
- Published
- 2004
28. [Who is responsible when the profit is low?].
- Author
-
Hammerstrøm J
- Subjects
- Drug Industry economics, Humans, Norway, Pharmacies economics, Privatization, Drug Costs, Economics, Pharmaceutical
- Published
- 2003
29. [National guidelines for treatment of chronic myelogenous leukemia].
- Author
-
Wisløff F, Brinch L, and Hammerstrøm J
- Subjects
- Adult, Aged, Blast Crisis, Humans, Hydroxyurea adverse effects, Hydroxyurea therapeutic use, Interferon-alpha therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Middle Aged, Norway, Practice Guidelines as Topic, Protein-Tyrosine Kinases antagonists & inhibitors, Transplantation, Homologous, Antineoplastic Agents therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Stem Cell Transplantation
- Published
- 2003
30. [Lead poisoning--a case report].
- Author
-
Amundsen T, Naess IA, Hammerstrøm J, Brudevold R, and Bjerve KS
- Subjects
- Bone Marrow Examination, Cooking and Eating Utensils, Diagnosis, Differential, Female, Humans, Middle Aged, Lead Poisoning diagnosis, Lead Poisoning etiology, Lead Poisoning therapy
- Abstract
Lead poisoning may cause irreversible health defects, including anaemia, central nervous system problems and various organ defects. We describe a patient with lead poisoning. A 54-year-old woman was admitted to hospital with anaemia and unspecific gastrointestinal symptoms. Peripheral blood smear and bone marrow aspirate showed basophilic stippling of erythrocytes suggestive of lead poisoning, which was confirmed by high concentrations of lead in her blood. The lead source was the glazing of a ceramic wine jug. Chelating therapy was started. Haemoglobin was normalised; the patient returned to work after nine months. Correct diagnosis and treatment can prevent serious health problems caused by lead poisoning.
- Published
- 2002
31. [Lead poisoning--an overview].
- Author
-
Amundsen T, Naess IA, Hammerstrøm J, Brudevold R, and Bjerve KS
- Subjects
- Acute Disease, Adult, Child, Chronic Disease, Environmental Exposure adverse effects, Female, Humans, Male, Occupational Exposure adverse effects, Lead Poisoning complications, Lead Poisoning diagnosis, Lead Poisoning etiology, Lead Poisoning therapy
- Abstract
Material and Methods: We present a review of the history, pathophysiology, diagnosis and treatment of lead poisoning based on relevant literature., Results and Interpretation: The human body does not metabolize lead, and lead accumulation may cause organ failure. Lead poisoning may cause serious health defects, including anaemia, central nervous system problems and various organ defects. Sources of lead may be found in the home as well as in the workplace or elsewhere in our environment, but lead poisoning is an infrequent condition. Prevention is important, but manifest lead poisoning can be treated effectively.
- Published
- 2002
32. [Warfarin treatment of venous thromboembolism].
- Author
-
Andersen IA and Hammerstrøm J
- Subjects
- Adult, Aged, Female, Humans, International Normalized Ratio, Male, Middle Aged, Norway, Patient Education as Topic, Patient Satisfaction, Quality Indicators, Health Care, Retrospective Studies, Surveys and Questionnaires, Ambulatory Care standards, Anticoagulants administration & dosage, Quality Assurance, Health Care, Thromboembolism drug therapy, Venous Thrombosis drug therapy, Warfarin administration & dosage
- Abstract
Background: Warfarin treatment of venous thromboembolism is the most frequent cause of reported serious and fatal adverse events associated with drug therapy in Norway. We assessed quality of treatment during transfer from hospital to community-based care., Material and Methods: 66 out of 100 consecutive patients with venous thromboembolism were studied by a retrospective survey that included data from hospital records and a questionnaire survey., Results: Time in therapeutic range was 57% during the first four weeks. Undertreatment was the most frequent deviation. Some patients reported a long time lag from INR measurement to dose prescription in community care; 42% did not receive written treatment information. There were six recurrences, but no serious or fatal bleeding complications during one year of observation. Patient satisfaction with information and treatment organisation was high., Interpretation: There is room for improvement of patient information and treatment quality in outpatient care in our area.
- Published
- 2002
33. [Intensive chemotherapy in Burkitt's lymphoma and aggressive non-Hodgkin's lymphoma].
- Author
-
Holte H, Smeland S, Blystad AK, Kvaløy S, Hammerstrøm J, and Tjønnfjord GE
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Burkitt Lymphoma mortality, Disease-Free Survival, Female, Follow-Up Studies, Humans, Lymphoma, Non-Hodgkin mortality, Male, Middle Aged, Retrospective Studies, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Burkitt Lymphoma drug therapy, Lymphoma, Non-Hodgkin drug therapy
- Abstract
Background: Clinical studies over the last 20 years using more intensive cytostatic regimens show improved results in children and adolescents with aggressive non-Hodgkin's lymphoma and in adult patients specifically with Burkitt's lymphoma., Material and Methods: We present a retrospective analysis of the use of the Berlin-Frankfurt-Munster (BFM) regimen for patients older than 15 years from three Norwegian university hospitals during the 1992-99 period., Results: Survival data for 24 patients 15-69 years old with Burkitt's lymphoma/B-cell acute lymphoblastic leukaemia (B-ALL) show an estimated overall five year survival of 70% (75% for Burkitt's lymphoma only). Eight of ten adolescent patients 15-20 years old with other aggressive lymphomas were alive and disease free at last follow-up. All nine patients given the regimen after failure of prior therapy died of lymphoma within six years., Interpretation: The BFM regimen yields impressive results as the primary treatment of adolescent and adult patients with Burkitt's lymphomas/B-ALL.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.